Representing a number of global biopharmaceutical and medical device companies and consistently handling major deals in the Chinese healthcare and life sciences market, Ropes & Gray LLP deservedly retains its place at the apex of this market. Practice head and Asia regional managing partner Arthur Mok has a wealth of experience in the field and is particularly recommended for advice on acquisitions and commercial agreements in the immunology space. Regulatory, compliance and enforcement expert Katherine Wang and healthcare IP specialist Geoffrey Lin are also integral. Eric Wu, who has first-hand industry experience having worked in-house for Johnson & Johnson, is another name to note.
Legal 500 Editorial commentary
Key clients
- Everest Medicines
- LianBio
- Pediatrix Therapeutics
- Tianjin Adicon Limited
- Luca Healthcare
- Bain Capital Life Sciences/Bain Capital Private Equity
- HUTCHMED
- Zenas BioPharma
- MediBoston
Work highlights
- Advising Everest Medicines on a commercial agreement with Accelerate Technologies for COVID-19 products and with Gilead Sciences for the development of cancer drug, Trodelvy.
- Representing Pediatrix Therapeutics in a license agreement with Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases in Greater China.
- Advised HUTCHMED on its license to Takeda to develop and commercialize Fruquintinib outside China for a total of US$ 1.13 billion, plus royalties and net sales.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
The lawyer(s) leading their teams.
Arthur Mok